States/Cities/Territories
States/Cities/Territories
For CPT™ 1999, the Vaccines/Toxoids section of codes was substantially revised. Multiple vaccine codes for the same vaccine type were created in several cases to reflect differences in formulations, dosages, and immunization schedules. These differences are already generally reflected in the CVX codes for use in the HL7 data transmission standard by immunization registries. In order to assist providers and immunization registry developers in the accurate coding of vaccine products administered, the products currently available in the U.S. for Haemophilus influenzae type b , hepatitis B , hepatitis A , influenza virus , and typhoid vaccines are listed here and mapped to the appropriate CPT™ 2001 and CVX codes. Questions may be directed to Julie Gamez at fzw4@cdc.gov or (404) 639-8169. Updates to this information will be made available at http://www.cdc.gov/nip/registry.
Disclaimer: All attempts have been made to verify the accuracy of this information, but it should not be relied upon for clinical decision-making. No endorsement of the manufacturers or products listed here is implied. CPT™ codes are copyright by the American Medical Association.
| CPT | CVX | conjugate formulation | schedule | brand name | manufacturer |
| 90645 | 47 | HbOC (diphtheria CRM197 protein/oligosaccharide) | 4 doses | HibTITER® | Wyeth-Ayerst |
| 90646 | 46 | PRP-D (diphtheria toxoid) | booster use only | ProHIBiT® | Aventis Pasteur Inc. |
| 90647 | 49 | PRP-OMP (outer membrane protein) | 3 doses | PedvaxHIB® | Merck &Co., Inc. |
| 90648 | 48 | PRP-T (tetanus toxoid) | 4 doses |
ActHIB® OmniHIB® |
Aventis Pasteur Inc. GlaxoSmithKline |
| In the Hib CPT code descriptors, information about the schedule is included to help providers identify the correct code. This does not necessarily mean that the number of doses specified is required to be given. For children who start the Hib immunization series late, fewer doses may be required. For children who start on time, four doses (at 2, 4, 6, 12-15 months) is the recommended schedule when using HbOC or PRP-T conjugates. Three doses (at 2, 4, 12-15 months) is the recommended schedule when using PRP-OMP conjugates. PRP-D conjugate is only appropriate for the booster dose at 12-15 months. | |||||
| Engerix-B® (GlaxoSmithKline) | ||||
| CPT | CVX | formulation |
dosage/volume (schedule) |
appropriate for... |
| 90744 | 08 | pediatric/ adolescent dose | 10 mcg/0.5 mL | all infants, children, and adolescents |
| 90746 | 43 | adult dose | 20 mcg/1.0 mL | adults >19 years |
| 90747 | 44 | dialysis or immunosuppressed dose | 40 mcg/2.0 mL (4 dose schedule) | adult hemodialysis or immunocomprimised |
| Recombivax HB® (Merck & Co, Inc.) | |||||
| CPT | CVX | formulation |
dosage/volume (schedule) |
color code | appropriate for... |
| 90744 | 08 | pediatric** | 2.5 mcg/0.5 mL | brown | normal infants children 1-10 years |
| 90745 | 42 | adolescent/ high-risk infant^^ | 5 mcg/0.5 mL | yellow | high risk infants adolescents 11-19 years |
| 90744 | 08 | pediatric/ adolescent | 5 mcg/0.5 mL | yellow | all infants, children, and adolescents 0-19 years |
| 90746 | 43 | adult~~ | 10 mcg/1.0 mL (3 dose schedule) |
green |
adults >= 20 years |
| 90743 | 43 | adult~~ | 10 mcg/1.0 mL (2 dose schedule) | green | adolescents 11-15 years |
| 90740 | 44 | adult dialysis or immunosuppressed dose | 40 mcg/1.0 mL (3 dose schedule) | blue | adult predialysis/dialysis |
** formulation discontinued as of August 1998 ^^ formulation re-named as of August 1998 ~~2 dose schedule, adult formulation, for adolescents was approved by FDA in September 1999
For CPT 2001, CPT code 90743 was added for the the 2-dose schedule of the adult formulation. It is recommended to use CPT code 90743 and CVX code 43 for adolescents who receive the 2- dose schedule of the adult formulation and CPT code 90746 and CVX code 43 for adults who receive the 3-dose schedule of the adult formulation.
Because of the 1998 change by Merck, CPT codes 90744 and 90745 and CVX codes 08 and 42 were ambiguous. CPT code 90745 was deleted in CPT 2000. It is recommended to use CPT code 90744 and CVX code 08 for all pediatric/adolescent Hepatitis B vaccine products.
|
Havrix® (GlaxoSmithKline) |
||||
| CPT | CVX | formulation | dosage/volume | schedule |
| 90632 | 52 | adult | 1440 ELU/1.0 mL | 2 doses |
| 90633 | 83 | pediatric/adolescent | 720 ELU/0.5 mL | 2 doses |
| 90634 | 84 | pediatric/adolescent | 360 ELU/0.5 mL | 3 doses |
| VAQTA® (Merck & Co., Inc.) | ||||
| 90632 | 52 | adult | 50 U/1.0 mL | 2 doses |
| 90633 | 83 | pediatric/adolescent | 25 U/0.5 mL | 2 doses |
|
CPT |
CVX | formulation | dosage | appropriate for... | brand name | manufacturer |
| 90657 | 15 | split virus | 0.25mL | 6-35 months |
Fluzone®split Fluvirin® Fluogen® Flushield® |
Aventis Pasteur Inc. PowerJect Parkedale Wyeth-Ayerst |
| 90658 | 15 | split virus | 0.5mL | 3 years |
Fluzone®split Fluvirin® Fluogen® Flushield® |
Aventis Pasteur Inc. PowerJect Parkedale Wyeth-Ayerst |
| 90659 | 16 | whole virus | 0.5mL | > 12 years | Fluzone®whole | Aventis Pasteur Inc. |
| CPT | CVX | formulation | brand name | manufacturer |
| 90690 | 25 | Live, Oral, Ty21a capsules | VIVOTIF BERNA® | Berna Products (Swiss Serum and Vaccine Institute) |
| 90691 | 101 |
Vi capsular polysaccharide (ViCPs) |
TYPHIM Vi® | Aventis Pasteur Inc. |
| 90692 | 41 | Heat- & Phenol- Inactivated (H-P) | generic | Wyeth-Ayerst |
| 90693 | 53 | Acetone- Inactivated/Killed, Dried (AKD) | generic (available only to military) | Wyeth-Ayerst |